vTv Therapeutics (VTVT) CFO granted 44,969 stock options at $36.92

Rhea-AI Filing Summary

vTv Therapeutics Inc. executive vice president and CFO Michael Stephen Tung received a grant of employee stock options reported as a Form 4 transaction. The award covers 44,969 options with an exercise price of $36.92 per share, increasing his directly held option position to 89,969 options following the grant. According to the footnote, the options vest 25% on the first anniversary of the grant date and then in equal quarterly installments afterward, spreading the ability to exercise over time.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tung Michael Stephen

(Last) (First) (Middle)

C/O VTV THERAPEUTICS INC.

3980 PREMIER DRIVE, SUITE 310

(Street)

HIGH POINT NC 27265

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
vTv Therapeutics Inc. [ VTVT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee stock option (right to buy)	$36.92	02/17/2026		A		44,969		(1)	02/17/2036	Class A Common Stock	44,969	$36.92	89,969	D

Explanation of Responses:

1. The options vest 25% on the first anniversary of the grant date and in quarterly equal installments thereafter.

Remarks:

	/s/ Elizabeth Keiley, as Attorney-in-fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did vTv Therapeutics (VTVT) report for Michael Stephen Tung?

vTv Therapeutics reported that EVP and CFO Michael Stephen Tung received an option grant for 44,969 shares. The grant is an employee stock option award, not an open-market purchase, and is structured as equity compensation for his executive role.

How many options were granted to the vTv Therapeutics (VTVT) CFO and at what price?

The CFO was granted 44,969 employee stock options with an exercise price of $36.92 per share. This price is the amount he must pay per share to exercise the options once they become vested and exercisable under the grant terms.

What is Michael Stephen Tung’s total vTv Therapeutics (VTVT) option holdings after this grant?

After the reported grant, Michael Stephen Tung holds a total of 89,969 employee stock options directly. This figure reflects all options reported as beneficially owned following the transaction, combining the newly granted award with his prior option holdings.

How do the newly granted vTv Therapeutics (VTVT) options vest for the CFO?

The granted options vest 25% on the first anniversary of the grant date, then in equal quarterly installments thereafter. This schedule gradually makes portions of the award exercisable over time, encouraging continued service and alignment with company performance.

Is the vTv Therapeutics (VTVT) CFO’s reported option grant a buy or sell transaction?

The transaction is an acquisition of derivative securities through a grant, not a market buy or sell. It is coded as a grant, award, or other acquisition, reflecting standard equity compensation rather than trading vTv Therapeutics shares on the open market.

Does the vTv Therapeutics (VTVT) Form 4 indicate direct or indirect ownership of the options?

The Form 4 shows the options as held with direct ownership by Michael Stephen Tung. The ownership code is listed as direct, and there is no indication of holding through a trust, LLC, or other indirect ownership entity in the reported transaction.